Header Logo

Connection

Wendy Stevens to Mutation

This is a "connection" page, showing publications Wendy Stevens has written about Mutation.
Connection Strength

1,416
  1. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
    View in: PubMed
    Score: 0,433
  2. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses. 2012 Feb; 28(2):171-5.
    View in: PubMed
    Score: 0,339
  3. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,123
  4. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr. 2009 Dec; 52(5):655-6.
    View in: PubMed
    Score: 0,076
  5. Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program. Pediatr Infect Dis J. 2009 Dec; 28(12):1123-5.
    View in: PubMed
    Score: 0,076
  6. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109.
    View in: PubMed
    Score: 0,055
  7. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 03; 603(7902):679-686.
    View in: PubMed
    Score: 0,044
  8. Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance. Sci Rep. 2018 10 25; 8(1):15751.
    View in: PubMed
    Score: 0,035
  9. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018 10 01; 73(10):2667-2674.
    View in: PubMed
    Score: 0,035
  10. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.
    View in: PubMed
    Score: 0,032
  11. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016 Nov; 16(11):e267-e275.
    View in: PubMed
    Score: 0,030
  12. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 09 15; 214(6):873-83.
    View in: PubMed
    Score: 0,030
  13. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82.
    View in: PubMed
    Score: 0,025
  14. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17; 26(11):1345-54.
    View in: PubMed
    Score: 0,023
  15. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012 Sep; 55(5):737-45.
    View in: PubMed
    Score: 0,022
  16. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):23-31.
    View in: PubMed
    Score: 0,021
  17. Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children. AIDS Res Hum Retroviruses. 2009 Nov; 25(11):1141-8.
    View in: PubMed
    Score: 0,019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.